ArticleScientific reports2025
Supplementation with oviductal EVs from the estrus, metestrus, and diestrus stages improved developmental competence of IVF mouse embryos.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reproductive fluids, commercial media, and organoids: bridging the gap in IVF culture systems.Human reproduction open · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Several studies showed that supplementation of oviductal extracellular vesicles (EVs) enhanced the development and quality of the early embryos cultured in vitro. However, our previous study found that the characteristics and the cargos of oviductal EVs varied across the proestrus, estrus, metestrus, and diestrus stages of the mouse estrous cycle. We hypothesized that the addition of EVs from the different stages may have different effects on embryonic development. This study aimed to evaluate the effect of oviductal EVs isolated from the different stages of the mouse estrous cycles on the development of in vitro fertilization (IVF) embryos. Experiment 1 evaluated the effect of oviductal EVs from the proestrus (Pro-EVs), estrus (Est-EVs), metestrus (Met-EVs), and diestrus (Die-EVs) stages on embryonic development. Experiment 2 examined the effect of different addition modes (0-4 EVs, 1-4 EVs, 2-4 EVs, 3-4 EVs and Re-EVs) on embryo development competence. Oviductal EVs were successfully isolated from the four estrous cycle stages, and their characterizations were described. Co-culture of mouse embryos with Est-EVs, Met-EVs and Die-EVs significantly improved the blastocyst yield and hatching rates regardless of supplemental dosages. When the embryos were obtained at 2-cell stage and cultured to the hatched stage, the blastocyst rate significantly increased in the 1-4 EVs, 2-4 EVs and 3-4 EVs groups compared to the control groups. The hatching rate in the 3-4 EVs group was significantly higher than in the other three groups. When 3-8 cells stage embryos were cultured to the hatching stage, the blastocyst and hatching rates significantly increased in the 2-4 EVs and 3-4 EVs groups comparing to the control group, but there were no significant differences between the 2-4 EVs and 3-4 EVs groups. When the embryos at morula stage were cultured, the blastocyst and hatching rates in the 3-4 EVs group were significantly higher than the control group. Die-EVs renewal did not improve the blastocyst formation and hatching rates but significantly increased the blastocyst cell number compared to the 0-4 EVs addition mode. The supplementation with oviductal EVs from the estrus, metestrus, and diestrus stages improved the blastocyst yield and hatching rates of IVF embryos. The different addition modes significantly affected the blastocyst rate of early embryos at the different developmental stages (2-cell, 3-8 cells and morula).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.